Revolutionary Technology Enhancing Cancer Surgery
In the realm of breast cancer treatment, the introduction of innovative tools has revolutionized the way surgical procedures are performed. Perimeter Medical Imaging AI, Inc. has announced groundbreaking results from a pivotal clinical trial studying its B-Series Optical Coherence Tomography (OCT) system combined with ImgAssist AI 2.0. This advanced technology is set to redefine intraoperative margin assessment during breast-conserving surgeries.
Significant Improvements in Surgical Outcomes
The study demonstrated a remarkable capability of the B-Series OCT system to assist surgeons in effectively identifying and addressing residual cancer at surgical margins compared to conventional methods. This pivotal trial revealed a statistically significant reduction in the incidence of residual cancer found during surgeries, with a p-value of 0.0050 highlighting the robustness of the findings.
During this randomized, multi-center clinical trial, which involved 206 patients diagnosed with Stage 0-III breast cancer, the B-Series system's efficacy was assessed against current standard surgical practices that rely heavily on tactile exams and imaging techniques like ultrasound and specimen radiographs. The introduction of ImgAssist AI 2.0 integrates cutting-edge artificial intelligence into imaging, enhancing precision in surgical assessments.
Clinical Importance of the Findings
Dr. Sarah Butler, the Vice President of Clinical and Medical Affairs at Perimeter, expressed optimism about the trial results. She highlighted how the technology enables real-time decision-making for surgeons by efficiently analyzing the surgical margins. By identifying regions of concern proactively, the AI tool minimizes the likelihood of re-excisions, which can lead to better patient experiences and outcomes.
Adrian Mendes, the Chief Executive Officer of Perimeter, reflected on the broader implications for cancer treatment. He stated that the B-Series OCT technology provides both patients and surgeons with greater peace of mind. Surgeons can now operate with enhanced confidence, significantly lowering the chances of repeat surgeries that can be physically and emotionally taxing for patients.
Looking Ahead: FDA Submission and Future Steps
With the positive results from the pivotal trial, Perimeter is preparing to submit its Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA). The submission is anticipated to occur in early 2025, a step that could lead to the widespread adoption of this transformative technology in the surgical oncology field.
The company plans to conduct further analyses, including secondary endpoints, to ensure comprehensive understanding and optimization of the system's clinical applications. Future presentations at medical conferences are also on the horizon, where detailed results will be shared with the medical community.
Conference Call Announcement
As part of keeping stakeholders informed, Perimeter will hold a conference call at 5:00 pm ET. This event will provide a deeper dive into the trial results and the implications for surgical practices. Interested participants can join the discussion by calling the provided numbers or tuning into the live audio webcast available on the company's website.
About Perimeter Medical Imaging AI
Perimeter Medical Imaging AI, Inc. is dedicated to enhancing cancer surgery through ultra-high-resolution, real-time imaging technologies that aim to meet high unmet medical needs. With its current FDA-cleared Perimeter S-Series OCT system, the company is already making strides in providing detailed visualization during surgeries. The promising B-Series with ImgAssist AI represents the company's commitment to innovation and is supported by significant funding, showcasing a dedication to pioneering advancements in medical technology aimed at improving patient outcomes in cancer care.
Frequently Asked Questions
What is the B-Series OCT system?
The B-Series OCT system is an advanced imaging technology designed to assist surgeons during breast-conserving surgeries by providing real-time analysis of tissue margins.
How does ImgAssist AI enhance surgical procedures?
ImgAssist AI integrates artificial intelligence to improve the detection of residual cancer at surgical margins, allowing for more informed decisions during surgery.
What were the trial results for the B-Series OCT system?
The pivotal trial demonstrated a statistically significant reduction in the number of patients with residual cancer at surgical margins, supporting the system's effectiveness.
When will the FDA submission occur?
Perimeter plans to submit its Premarket Approval Application for the B-Series OCT system to the FDA in early 2025.
How can I access the conference call?
The conference call can be accessed by dialing the provided numbers or participating via the live audio webcast available on Perimeter's website.
